Arcus Biosciences (RCUS) Net Income towards Common Stockholders (2017 - 2026)
Arcus Biosciences (RCUS) recorded quarterly Net Income towards Common Stockholders of -$128.0 million in Q1 2026, down 20.75% quarter-over-quarter from -$106.0 million in Q4 2025, and down 14.29% on a YoY basis from -$149.3 million in Q1 2025.
Arcus Biosciences (RCUS) Net Income towards Common Stockholders (2017 - 2026) Analysis & Trends
Arcus Biosciences' Net Income towards Common Stockholders history runs 10 years deep, the most recent figure standing at -$128.0 million for Q1 2026.
- In Q1 2026, Net Income towards Common Stockholders fell 14.29% year-over-year to -$128.0 million; the TTM figure through Mar 2026 stood at -$369.0 million (up 5.63% YoY), while the FY2025 annual figure was -$353.0 million, down 24.73% from the prior year.
- Net Income towards Common Stockholders was -$128.0 million for Q1 2026 at Arcus Biosciences, down from -$106.0 million in the prior quarter.
- In the past five years, Net Income towards Common Stockholders ranged from a high of -$4.0 million in Q1 2024 to a low of -$135.0 million in Q3 2025.
- Historically, Net Income towards Common Stockholders has averaged -$83.6 million across 5 years, with a median of -$80.5 million in 2023.
- The sharpest annual moves came in 2024 and 2025: Net Income towards Common Stockholders jumped 95.0% in 2024, then sank 2700.0% in 2025.
- A 5-year view of Net Income towards Common Stockholders shows it stood at -$67.0 million in 2022, then declined by 20.9% to -$81.0 million in 2023, then slipped by 16.05% to -$94.0 million in 2024, then declined by 12.77% to -$106.0 million in 2025, then dropped by 20.75% to -$128.0 million in 2026.
- The last three Net Income towards Common Stockholders figures came in at -$128.0 million (Q1 2026), -$106.0 million (Q4 2025), and -$135.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -13.56 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 2.50 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.63 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Arcus Biosciences | 3.05 Bn | 2.23 Bn | - | -128.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -128.00 Mn |
| Dec 31, 2025 | -106.00 Mn |
| Sep 30, 2025 | -135.00 Mn |
| Mar 31, 2025 | -112.00 Mn |
| Dec 31, 2024 | -94.00 Mn |
| Sep 30, 2024 | -92.00 Mn |
| Jun 30, 2024 | -93.00 Mn |
| Mar 31, 2024 | -4.00 Mn |
| Dec 31, 2023 | -81.00 Mn |
| Sep 30, 2023 | -71.00 Mn |
| Jun 30, 2023 | -75.00 Mn |
| Mar 31, 2023 | -80.00 Mn |
| Dec 31, 2022 | -67.00 Mn |
| Sep 30, 2022 | -65.00 Mn |
| Jun 30, 2022 | -67.00 Mn |
| Mar 31, 2022 | -68.00 Mn |
| Dec 31, 2021 | 279.54 Mn |
| Sep 30, 2021 | -77.98 Mn |
| Jun 30, 2021 | -75.97 Mn |
| Mar 31, 2021 | -72.59 Mn |